SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
DogecoinVM Makes DOGE Transactions 300x Faster 
Trump Signs Order to Cut Routine Childhood Vaccines 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission 
Tabletop particle accelerator could transform medicine and materials science 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Trump Opens Tax-Exempt Dyed Diesel Access as Fuel Prices Surge 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Constellation Brands Beats Q2 Estimates, Buys SpikedAde 
Marvell Stock Surges on $90 Billion AI Revenue Outlook 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Paramount Skydance Completes $110 Billion Warner Bros Discovery Deal 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Add as a preferred source on Google
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
